Med-X, Inc. Sample Contracts

FORM OF COMMON STOCK PURCHASE WARRANT MED-X, INC.
Common Stock Purchase Warrant • February 9th, 2024 • Med-X, Inc. • Pharmaceutical preparations • New York

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [_____], 20281 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Med-X, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and The Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to a Holder’s right to elec

Broker-Dealer Agreement
Broker-Dealer Agreement • September 19th, 2022 • Med-X, Inc. • Pharmaceutical preparations

This agreement (together with exhibits and schedules, the “Agreement”) is entered into by and between MED-X, INC. (“Client”), a Nevada Corporation, and Dalmore Group, LLC., a New York Limited Liability Company (“Dalmore”). Client and Dalmore agree to be bound by the terms of this Agreement, effective as of February 23, 2021 (the “Effective Date”):

●] SHARES OF COMMON STOCK MED-X, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • October 27th, 2023 • Med-X, Inc. • Pharmaceutical preparations • New York

The undersigned, MED-X, INC., a company incorporated under the laws of Nevada (the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which MAXIM GROUP LLC (“Maxim”) is acting as representative to the several Underwriters (in such capacity, the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.

WARRANT AGENCY AGREEMENT
Warrant Agency Agreement • February 9th, 2024 • Med-X, Inc. • Pharmaceutical preparations

WARRANT AGENCY AGREEMENT (this “Warrant Agreement”) dated as of [____], 2023 (the “Issuance Date”) between Med-X, Inc., a company incorporated under the laws of the State of Nevada (the “Company”), and VStock Transfer, LLC (the “Warrant Agent”).

MED-X, INC. UNDERWRITING AGREEMENT [●] Shares of Common Stock
Underwriting Agreement • September 19th, 2022 • Med-X, Inc. • Pharmaceutical preparations • New York

Med-X, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom EF Hutton, division of Benchmark Investments, LLC (“EF Hutton”), is acting as the representative (the “Representative”), an aggregate of [●] shares (the “Firm Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”). The Company also proposes to issue and sell to the Underwriters, upon the terms and conditions set forth herein, up to an additional [●] shares of Common Stock (the “Option Shares”), representing 15% of the Firm Shares, as may be necessary to cover over-allotments made in connection with the offering. The Option Shares and the Firm Shares are referred to collectively herein as the “Securities.”

REGISTRATION RIGHTS AGREEMENT August 5, 2021
Registration Rights Agreement • September 19th, 2022 • Med-X, Inc. • Pharmaceutical preparations • New York

This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), is made and entered into as of the date first above written, by and among MED-X, INC., a Nevada corporation and having a principal place of business at 8236 Remmet Avenue, Canoga Park, California 91304 (the “Company”), GEM GLOBAL YIELD LLC SCS, a “société en commandite simple” formed under the laws of Luxembourg having LEI No. 213800CXBEHFXVLBZO92 and an address at 12C, rue Guillaume J. Kroll, L-1882, Luxembourg (“Purchaser”); and GEM YIELD BAHAMAS LIMITED, a limited company formed under the laws of the Commonwealth of the Bahamas and having an address at 3 Bayside Executive Park, West Bay Street & Blake Road, P.O. Box N-4875, Nassau, The Bahamas (“GYBL,” and together with Purchaser, the “Parties”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement.

●] UNITS EACH UNIT CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK MED-X, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • February 9th, 2024 • Med-X, Inc. • Pharmaceutical preparations • New York

The undersigned, MED-X, INC., a company incorporated under the laws of Nevada (the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which MAXIM GROUP LLC (“Maxim”) is acting as representative to the several Underwriters (in such capacity, the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.

POSTING AGREEMENT
Posting Agreement • December 21st, 2015 • Med-X, Inc. • Pharmaceutical preparations • Delaware

THIS POSTING AGREEMENT (the "Agreement") is made as of this 12th day of November, 2015, between StartEngine Crowdfunding, Inc. ("StartEngine"), a Delaware corporation,and Med-X, Inc., a Nevada corporation (the "Company"), to act as the Company's online intermediary technology platform (the "Platform") in connection with the Company's proposed private placement offering (the "Offering") of common or preferred stock (the "Securities").

SHARE PURCHASE AGREEMENT dated as of August 5, 2021 by and among MED-X, INC. GEM GLOBAL YIELD LLC SCS and GEM YIELD BAHAMAS LIMITED
Share Purchase Agreement • September 19th, 2022 • Med-X, Inc. • Pharmaceutical preparations • New York

This SHARE PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of the date first above written and is effective as of August 5, 2021 (the “Effective Date”) by and among MED-X, INC., a Nevada corporation and having a principal place of business at 8236 Remmet Avenue, Canoga Park, California 91304 (the “Company”); GEM GLOBAL YIELD LLC SCS, a “société en commandite simple” formed under the laws of Luxembourg having LEI No. 213800CXBEHFXVLBZO92 having an address at 12C, rue Guillaume J. Kroll, L-1882, Luxembourg (the “Purchaser”); and GEM YIELD BAHAMAS LIMITED, a limited company formed under the laws of the Commonwealth of the Bahamas and having an address at 3 Bayside Executive Park, West Bay Street & Blake Road, P.O. Box N-4875, Nassau, The Bahamas (“GYBL,” and together with the Company and Purchaser, the “Parties”).

LICENSE AGREEMENT
License Agreement • September 23rd, 2022 • Med-X, Inc. • Pharmaceutical preparations • California

This License Agreement (the “Agreement”) is made as of the 15th day of January, 2010 by and between Matthew Mills, an individual (“Licensor”), and Pacific Shore Holdings, Inc., a California corporation (“Licensee”).

TRI-PARTY ESCROW AGREEMENT
Tri-Party Escrow Agreement • March 10th, 2025 • Med-X, Inc. • Pharmaceutical preparations • Missouri

This ESCROW AGREEMENT (“Agreement”) is made and entered into as of March 20, 2024, by and among Med X, Inc., a Nevada Corporation (the “Company”), DealMaker Securities LLC, a Delaware limited liability company (the “Managing Broker-Dealer”) and ENTERPRISE BANK & TRUST, a Missouri chartered trust company with banking powers (in its capacity as escrow holder, the “Escrow Agent”).

POSTING AGREEMENT
Posting Agreement • May 23rd, 2019 • Med-X, Inc. • Pharmaceutical preparations • New York

THIS POSTING AGREEMENT (the “Agreement”) is made as of May 17, 2019, between StartEngine Crowdfunding, Inc. (“StartEngine”), a Delaware corporation, and Med-X, Inc. a Nevada corporation (the “Company”), to act as the Company’s online intermediary technology platform (the “Platform”) in connection with the Company’s proposed offering promulgated under Regulation A (“Reg A+”) under the Securities Act of 1933, as amended (the “Securities Act”), (the “Offering”) of common or preferred stock (the “Securities”).

Licensing Agreement
Licensing Agreement • March 10th, 2025 • Med-X, Inc. • Pharmaceutical preparations • California

This Agreement (“Agreement”) is entered into as of June 22, 2012 (“Effective Date”) by and between Dr. Morton I Hyson, M.D., P.C. d.b.a. Hyson Medical Products (“Dr. Hyson”, ‘‘HMP”) and Pacific Shore Holdings, Inc. (“PSH”). Dr. Hyson and PSH are hereinafter collectively referred to as the Parties or, individually, as a Party.

LINE OF CREDIT AGREEMENT
Line of Credit Agreement • March 10th, 2025 • Med-X, Inc. • Pharmaceutical preparations • California

THIS LINE OF CREDIT AGREEMENT (“Agreement”) is made and entered into effective as of the 6th day of August (the “Execution Date”) by and among MATTHEW MILLS and JENNIFER MILLS (collectively, the “Lender”) and MED-X, INC., a Nevada corporation (the “Borrower”).

PURCHASER’S RIGHTS AGREEMENT
Purchaser's Rights Agreement • October 3rd, 2023 • Med-X, Inc. • Pharmaceutical preparations • California

THIS PURCHASER’S RIGHTS AGREEMENT (this “Agreement”), is made as of the 15th day of September, 2023, by and among NAPCO Painting Contractors, Inc., a California corporation (the “Company”) Med-X, INC., a Nevada corporation (the “Purchaser”), and Joseph Winograd (the “Seller”).

DEVELOPMENT, MARKETING AND CONSULTING AGREEMENT
Development, Marketing and Consulting Agreement • September 20th, 2016 • Med-X, Inc. • Pharmaceutical preparations • California

This Development, Marketing and Consulting Agreement (“Agreement”) is entered into on April 25, 2016, (“Effective Date”) by and between MEDX, Inc. (“MEDX”), a Nevada corporation, and M6, Ltd., a Private Limited Company based in London, United Kingdom (“M6”).

DISTRIBUTION AGREEMENT
Distribution Agreement • October 3rd, 2023 • Med-X, Inc. • Pharmaceutical preparations • California

ENSYSTEX AUSTRALASIA PTY LTD whose principal place of business is at Warehouse D, Building 6, The Switchyard, 161 Manchester Road, Auburn NSW 2144, AUSTRALIA; hereinafter referred to as ‘ENSYSTEX’. WHEREAS

AMENDMENT TO PROMISSORY NOTE
Promissory Note • October 3rd, 2023 • Med-X, Inc. • Pharmaceutical preparations

THIS AMENDMENT TO PROMISSORY NOTE (this “Agreement”), dated as of September 28, 2023, by and between MED-X, INC. (the “Borrower”) and MATTHEW MILLS and JENNIFER MILLS (the “Lender” and/or their successors and assigns (collectively, with the Lender, the “Holder”).

NMS Capital Advisors Engagement Letter
Engagement Agreement • May 23rd, 2019 • Med-X, Inc. • Pharmaceutical preparations

NMS Capital Advisors, LLC (“NMS”) is pleased to provide this Engagement Agreement (this “Agreement”) to Med-X, Inc. (the “Company”). The purpose of this Agreement is to set forth the terms and conditions under which NMS will act as the Company’s exclusive financial advisor with respect to the Company’s proposed sale of up to 25,0000,000 shares of common stock, par value $0.01 per share (the “Common Stock”), in a Regulation A+, Tier 2 offering (the “Reg A Transaction”).

THIRD AMENDMENT TO PROMISSORY NOTE AND LINE OF CREDIT AGREEMENT
Third Amendment to Promissory Note and Line of Credit Agreement • September 25th, 2026 • Med-X, Inc. • Agricultural chemicals

THIS THIRD AMENDMENT TO PROMISSORY NOTE AND LINE OF CREDIT AGREEMENT (this "Agreement"), dated as of September 8, 2026, by and between MED-X, INC. (the "Borrower") and MATTHEW MILLS and JENNIFER MILLS (the "Lender" and/or their successors and assigns (collectively, with the Lender, the "Holder")).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • September 25th, 2026 • Med-X, Inc. • Agricultural chemicals • Utah

This Securities Purchase Agreement (this “Agreement”), dated as of September 16, 2026, is entered into by and between MED-X, Inc., a Nevada corporation (“Company”), and Streeterville Capital, LLC, a Utah limited liability company (“Investor”). Capitalized terms used but not otherwise defined herein will have the meanings set forth in Section 13.

AMENDMENT TO PROMISSORY NOTE
Promissory Note Amendment • October 2nd, 2023 • Med-X, Inc. • Pharmaceutical preparations

THIS AMENDMENT TO PROMISSORY NOTE (this “Agreement”), dated as of September 28, 2023, by and between MED-X, INC. (the “Borrower”) and MATTHEW MILLS and JENNIFER MILLS (the “Lender” and/or their successors and assigns (collectively, with the Lender, the “Holder”).

AMENDMENT NO. 1 TO AGREEMENT FOR THE PURCHASE AND SALE OF CAPITAL STOCK
Agreement for the Purchase and Sale of Capital Stock • February 9th, 2024 • Med-X, Inc. • Pharmaceutical preparations

THIS AMENDMENT NO. 1 TO THE AGREEMENT FOR THE PURCHASE AND SALE OF CAPITAL STOCK (“Agreement”) by and between MED-X, INC. (“Purchaser”) and JOSEPH WINOGRADE (“Seller”) shall be deemed effective as of December 13, 2023.

August 29th, 2025 Cooper Lloyd, CEO Delbrook Digital Ltd. North Vancouver, BC V7K1V4 Canada Matthew Mills Med-X, Inc. Canoga Park CA 91304 Steve Carlson, CEO Marco Polo Securities Inc. New York, NY 10020 Dear All:
Engagement Agreement • September 8th, 2025 • Med-X, Inc. • Pharmaceutical preparations • New York

This Agreement shall confirm the engagement of Delbrook Digital Ltd., a foreign broker-dealer based in Canada doing business as Bad Twin Capital (together with any subsidiaries, affiliates, successors and assigns, “Bad Twin Capital”), along with its US partner, Marco Polo Securities, Inc., a registered US broker-dealer and member FINRA/ SIPC (together with its subsidiaries and affiliates, “Marco Polo”), by Med-X, Inc., a Nevada Corporation (together with any subsidiaries, affiliates, successors and assigns, the “Company” or “Med-X, Inc”) pursuant to which Bad Twin Capital and Marco Polo (together, the “Bad Twin Capital Team”) shall act as financial advisers to the Company. Additionally, the Company acknowledges that registered representatives of Marco Polo may also be employees of Pi Capital International LLC (“Pi Capital”), a financial services firm located at 1230 Avenue of the Americas, 16th Floor, New York, NY 10020. This Agreement sets forth the terms of such engagement.

AGREEMENT FOR THE PURCHASE AND SALE OF CAPITAL STOCK
Purchase and Sale of Capital Stock • October 3rd, 2023 • Med-X, Inc. • Pharmaceutical preparations

This Agreement ("Agreement") is made as of September 14, 2023 between Joseph Winograde (the "Seller") and Med-X, Inc. a Nevada corporation (the "Purchaser”).

AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTE
Convertible Promissory Note • February 9th, 2024 • Med-X, Inc. • Pharmaceutical preparations

THIS AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTE (“Agreement”), shall be deemed effective as of December 13, 2023, by and between MED-X, INC. (the “Company”) and JOSEPH WINOGRADE (the “Holder”).

Dear Mr. Matthew Mills, The purpose of this engagement letter is to outline our agreement in principle pursuant to which R. F. Laffe1ty & Co., Inc. (“Lafferty”) will act as the lead managing tlllderwriter and sole book running manager in connection...
Engagement Letter • April 28th, 2023 • Med-X, Inc. • Pharmaceutical preparations

This engagement letter states certain conditions and assumptions upon which the Offering is premised. However, except as expressly provided for herein, this engagement letter is not intended to be a binding legal document, with the exception of those specific sections of this engagement letter that are agreed to be binding. All references in this engagement letter to dollars or $ shall mean United States dollars.

AGREEMENT FOR THE PURCHASE AND SALE OF CAPITAL STOCK
Purchase and Sale of Capital Stock Agreement • September 21st, 2023 • Med-X, Inc. • Pharmaceutical preparations

This Agreement ("Agreement") is made as of September 14, 2023 between Joseph Winograde (the "Seller") and Med-X, Inc. a Nevada corporation (the "Purchaser”).

DISTRIBUTION AGREEMENT MED-X, INC and ENSYSTEX AUSTRALASIA PTY LTD
Distribution Agreement • September 27th, 2023 • Med-X, Inc. • Pharmaceutical preparations • California

ENSYSTEX AUSTRALASIA PTY LTD whose principal place of business is at Warehouse D, Building 6, The Switchyard, 161 Manchester Road, Auburn NSW 2144, AUSTRALIA; hereinafter referred to as ‘ENSYSTEX’.

STREETERVILLE CAPITAL, LLC November 2, 2026
Letter Agreement • November 5th, 2026 • Med-X, Inc. • Agricultural chemicals

This letter agreement (this “Letter Agreement”) is entered into by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and MED-X, Inc., a Nevada corporation (“Company”), in connection with that certain Securities Purchase Agreement dated September 16, 2026 between Investor and Company (the “Purchase Agreement”). Capitalized terms used but not otherwise defined herein will have the meanings ascribed to such terms in the Purchase Agreement. Investor and Company hereby agree as follows:

Amendment No. 1 to Engagement Agreement
Engagement Agreement • July 15th, 2019 • Med-X, Inc. • Pharmaceutical preparations • California

Reference is made to the Engagement Agreement, dated April 29, 2019, (the “Engagement Agreement”), by and between NMS Capital Advisors, LLC (“NMS”) and Med-X, Inc. (the “Company”). All capitalized terms used in this Amendment No. 1 to the Engagement Agreement (this “Amendment”) and not otherwise defined herein shall have the respective meanings assigned to such terms in the Engagement Agreement. NMS and the Company agree as follows:

AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTE
Convertible Promissory Note Amendment • February 9th, 2024 • Med-X, Inc. • Pharmaceutical preparations

THIS AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTE (“Agreement”), shall be deemed effective as of December 13, 2023, by and between MED-X, INC. (the “Company”) and JOSEPH WINOGRADE (the “Holder”).

CONFIDENTIAL September 15, 2026
Placement Agent Agreement • September 18th, 2026 • Med-X, Inc. • Agricultural chemicals • New York
ESCROW SERVICES AGREEMENT
Escrow Services Agreement • December 21st, 2015 • Med-X, Inc. • Pharmaceutical preparations • New York

This Escrow Services Agreement (this "Agreement") is made and entered into as of <date> by and between FundAmerica Securities, LLC ("FundAmerica Securities", or "Escrow Agent"), and Med-X, Inc. ("Issuer").

AGREEMENT OF MERGER AND PLAN OF REORGANIZATION BY AND AMONG MED-X, INC., MED-X ACQUISITION CORP and PACIFIC SHORE HOLDINGS, INC. and MATTHEW MILLS Dated as of December 15, 2017 AGREEMENT OF MERGER AND PLAN OF REORGANIZATION
Merger Agreement • December 21st, 2017 • Med-X, Inc. • Pharmaceutical preparations • Delaware

THIS AGREEMENT OF MERGER AND PLAN OF REORGANIZATION (this “Agreement”) is made and entered into on December 15, 2017, by and among Med-X, Inc., a Nevada corporation (“Parent”), Med-X Acquisition Corp, a Delaware corporation in formation (“Acquisition Corp”), which is a wholly-owned subsidiary of Parent, Pacific Shore Holdings, Inc., a Delaware corporation (the “Company”), and Matthew Mills, an individual (“Mills”).